Douglas W. Mapel, MD

Articles by Douglas W. Mapel, MD

Claims-Based Risk Model for First Severe COPD Exacerbation

ByRichard H. Stanford, PharmD, MS,Arpita Nag, PhD, MBA, MS,Douglas W. Mapel, MD,Todd A. Lee, PhD,Richard Rosiello, MD,Michael Schatz, MD,Francis Vekeman, MS,Marjolaine Gauthier-Loiselle, PhD,J.F. Philip Merrigan, PhD,Mei Sheng Duh, ScD

February 16th 2018

A health insurance claims-based risk assessment tool to predict patients’ first severe chronic obstructive pulmonary disease exacerbation has been developed and validated.

COPD-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenanc

ByAnand A. Dalal, PhD, MBA,Manan Shah, PhD,Anna O. D'Souza, PhD,Douglas W. Mapel, MD

March 16th 2011

Initiation of fluticasone propionate–salmeterol after a COPD-related hospitalization or ED visit decreased the risk of a recurrent event and reduced COPD-related medical costs.

Douglas W. Mapel, MD

Articles by Douglas W. Mapel, MD

Claims-Based Risk Model for First Severe COPD Exacerbation

COPD-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenanc

Latest Updated Articles

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

5 Ongoing Clinical Trials in Myeloproliferative Neoplasms

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”